Please wait while the transcript is being prepared...
0:00
The
content of this talk
will focus on the pharmacogenetic
prediction of treatment response
in psychiatry and will
include information
on the most significant
findings in the area
and their clinical applications.
0:14
The talk will be divided
into five chapters.
The first part will deal with the
causes of treatment variability.
The second part will explain the
contribution of genetic variance
in the metabolic enzymes
to treatment variability.
The third part will summarize
genetic findings related
to treatment response, followed by
a summary of genetic factors related
to side effects induced
by psychotropic drugs.
And finally, we will talk
about existing genetic tests
and their application for
the prediction of response
to psychotropic drugs.
0:48
We will start by talking on the
causes of treatment variability.
0:53
The mainstay treatment of
severe mental disorders
such as schizophrenia
and bipolar disorder
is the use of psychotropic drugs.
However, not all patients
respond to treatment.
30% to 50% of treated
patients fail to respond.
And about 60% to 70% percent
develop long-lasting and severe side
effects, which can be
become life threatening.
These side effects include
extrapyramidal side effects, weight
gain and other phenotypes
contributing to metabolic syndrome,
sexual dysfunction,
and suicidal ideation.
Psychotropic drugs have a
complex pharmacological profile.
They target a variety of
neurotransmitter systems.
However, it is not
clear which targets
are important for the
therapeutic action,
and the mechanism of action of
psychotropic drops remains unclear.
Pharmacogenetic studies try to
identify genetic variance that
influence treatment
response and contribute
to the development of side effects.
The identification of
response-related variance
will help to discern targets
of therapeutic value.
This information might help to
predict treatment response based
on the genetic predisposition
of the patient.
